Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide + hydroxychloroquine for primary Sjögren's syndrome
NL-OMON55143Phase 2Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Leflunomide + hydroxychloroquine with Placebo then active crossover (2 arms). Primary endpoint: Change in ESSDAI score from baseline to week 24. Started Oct 2021; status: recruiting.
02
Drugs
leflunomidehydroxychloroquine
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON55143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55143.